Group 1 - The company has placed significant emphasis on the development of its overseas business in recent years [2] - The business scope has expanded to countries and regions such as Russia, the Middle East, and South America [2] - Currently, overseas business accounts for a low proportion of the company's overall operations and is in a stage of development and growth [2]

Core Viewpoint - The company, Zhongyida, confirmed that its production and operations are normal and will disclose its 2025 annual performance forecast by January 30, 2026, indicating no undisclosed information [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - The company adheres to regulatory requirements regarding performance disclosures [2] - There is a clear timeline for the upcoming performance forecast release [2]

Core Viewpoint - The company has recently disclosed its preliminary earnings forecast for the year 2025, indicating a significant expected loss in net profit [2] Financial Performance - The preliminary estimate for the net profit attributable to shareholders for 2025 is projected to be between -58 million and -52 million yuan [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to range from -56.3 million to -50.3 million yuan [2]

证券日报网讯 2月9日，红日药业在互动平台回答投资者提问时表示，2026年相关数据属于未披露数 据，请关注定期报告和公告。 （文章来源：证券日报） ...

证券日报网讯 2月9日，恒运昌在互动平台回答投资者提问时表示，公司拟在北京、上海、武汉、合肥 等晶圆制造集中的区域设置营销及技术支持中心，每个中心配备专业的技术支持、营销和市场团队，以 缩短客户响应时间并能够迅速响应客户的个性化需求，为客户提供更加精准和定制化的技术服务。此 外，区域营销及技术支持中心还能直接参与到与终端晶圆厂商的合作过程中，第一时间获悉先进制程对 核心零部件的最新技术要求，为公司在技术研发和产品创新的方向提供了重要反馈，同时也为后续产品 的升级与商业化奠定了坚实基础。公司通过设立北京子公司"恒运昌京昇半导体科技（北京）有限公 司"，加强公司在华北地区的业务开拓，发挥产品生产、区域业务协调、品牌建设、资源整合、客户维 护、吸引高科技及技术人才、强化科研能力等功能，统筹区域内优势资源，扩展业务服务半径。未来公 司将逐步在上海、武汉、合肥等晶圆制造集中的区域设立分支机构，完善区域布局，进一步提高对行业 头部客户的服务能力以及对重点市场的挖掘和渗透能力。 （文章来源：证券日报） ...

证券日报网讯 2月9日，赛维时代在互动平台回答投资者提问时表示，公司将持续优化经营管理，致力 于提升经营效益和投资回报，回馈广大投资者的信任。 （文章来源：证券日报） ...

Group 1 - The company stated that its product prices are influenced by various factors including market supply and demand, as well as industry competition [2] - The company follows a market-oriented pricing principle, determining product prices based on market conditions and production costs among other factors [2]

证券日报网2月9日讯 ，神州细胞在接受调研者提问时表示，公司2025年研发投入初步测算在83000万元 ~87000万元区间。由于多个项目陆续进入中后期临床研究阶段，公司研发投入也会持续维持高位。公 司目前仍处于成长期，高额研发投入是未来发展的保障，这也是创新药研发企业的共同特点。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 2月9日，同益股份在互动平台回答投资者提问时表示，截至2026年1月30日，公司股东总 数为19907户。 ...

Core Viewpoint - The company faces challenges in its performance primarily due to the slow recovery of demand in the construction waterproofing industry, proactive optimization of its business structure to reduce the proportion of risky operations, and the prudent decision to make impairment provisions [2] Group 1: Company Performance - The company is experiencing performance challenges linked to the slow recovery in the construction waterproofing sector [2] - Management is committed to diligent governance and risk control measures under the leadership of the board [2] - The company is focused on high-quality development strategies, emphasizing retail, construction, and overseas market expansion [2] Group 2: Risk Management and Investor Relations - The company is enhancing accounts receivable management and cost control to improve operational quality [2] - There is a strong emphasis on valuing shareholder opinions, with efforts to maintain investor rights through standardized operations and continuous improvement [2]